martes, 8 de septiembre de 2020

Coronavirus drugs research firm WuXi Biologics’ largest shareholder sells stake for US$893 million windfall | South China Morning Post

Coronavirus drugs research firm WuXi Biologics’ largest shareholder sells stake for US$893 million windfall | South China Morning Post

STAT China

Jonathan Chan

More reads

  • WuXi Biologics’ largest shareholder sells stake for $893 million windfall (South China Morning Post)
  • China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor (Endpoints News)
  • Chinese biopharma firm Adlai Nortye raises $100M In Series C round (China Money Network)
  • China's CNBG, Sinovac find more countries to test coronavirus vaccines (Reuters)

No hay comentarios: